BRIEF published on 09/24/2024 at 23:05, 1 year 5 months ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 1 year 5 months ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 1 year 6 months ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 1 year 6 months ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 1 year 6 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 1 year 6 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 1 year 6 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 1 year 6 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 1 year 6 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
PRESS RELEASE published on 08/21/2024 at 13:00, 1 year 6 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
Published on 03/20/2026 at 00:20, 1 hour 45 minutes ago Prospect Ridge To Host Investor Webinar With Presentation And Audience Q&A
Published on 03/20/2026 at 00:20, 1 hour 45 minutes ago Reeflex Solutions Inc. Announces Revocation of Management Cease Trade Order
Published on 03/19/2026 at 21:16, 4 hours 49 minutes ago Unusual Machines, Inc. Announces Proposed Public Offering
Published on 03/19/2026 at 14:20, 11 hours 45 minutes ago CBMJ CEO Rips Legacy Liberal Media Over Iran Coverage on The Schaftlein Report
Published on 03/19/2026 at 13:50, 12 hours 15 minutes ago Predictiv AI Appoints Multi-Agent Systems Pioneer Professor George Rzevski as Strategic Advisor to Advance Swarm AI Platforms
Published on 03/19/2026 at 23:48, 2 hours 17 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3C daily buy back notice
Published on 03/19/2026 at 22:55, 3 hours 10 minutes ago Baristas behind millions of cups of coffee compete globally
Published on 03/19/2026 at 22:48, 3 hours 17 minutes ago EQS-Adhoc: Forecast for the 2026 financial year
Published on 03/19/2026 at 19:24, 6 hours 41 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/19/2026 at 18:00, 8 hours 5 minutes ago Filing of the 2025 Universal Registration Document
Published on 03/19/2026 at 08:45, 17 hours 20 minutes ago Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 19 hours 5 minutes ago bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 19 hours 5 minutes ago 2025 Annual results and new strategic signature
